In this multicenter study, belimumab effectively reduced disease activity in systemic lupus erythematosus patients with joint and skin manifestations, showing significant improvement in acute and subacute skin types earlier than in chronic types, while no significant benefit was observed for nonspecific skin manifestations.
41 citations
,
August 1988 in “Journal of The American Academy of Dermatology” In this case report, a patient with subacute cutaneous lupus erythematosus and exfoliative erythroderma achieved complete remission with systemic corticosteroids and long-term hydroxychloroquine.
33 citations
,
June 2021 in “Dermatologic Therapy” This study reports that a patient with subacute cutaneous lupus erythematosus experienced disease exacerbation after the first dose of the BNT162b2 mRNA COVID-19 vaccine, but tolerated the second dose without adverse reactions.
2 citations
,
January 2024 in “SAGE Open Medical Case Reports” In this case report, a 63-year-old male with rheumatoid arthritis, diabetes, hypertension, and peripheral neuropathy developed drug-induced subacute cutaneous lupus erythematosus after taking Dupilumab for chronic hand dermatitis.
October 2023 in “Indian Journal of Skin Allergy” This study discusses a rare case of subacute cutaneous lupus erythematosus induced by nab-paclitaxel, a complication scarcely reported in existing literature related to paclitaxel use.